Drug Profile
GUT 1
Alternative Names: GUT-1; MT-5745; STNM 01Latest Information Update: 30 Nov 2023
Price :
$50
*
At a glance
- Originator Stelic Institute & Co
- Developer Gut; Sameshima Hospital; Stelic Institute & Co
- Class Anti-inflammatories; Antifibrotics; Antiulcers
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ulcerative colitis
- Phase I Crohn's disease
Most Recent Events
- 14 Oct 2023 GUT 1 is still in phase II trials for Ulcerative colitis in Japan
- 14 Oct 2023 Safety and efficacy data from a phase I trial in Ulcerative colitis presented at the 31st United European Gastroenterology Week 2023 (UEGW-2023)
- 12 May 2021 Stelic Institute discontinues a phase I clinical trial for Ulcerative colitis and Crohn's disease (Treatment-experienced) in Japan (Submucosal) (UMIN000020900)